CN111093655A - 在酸性ph值下具有经增强活性的抗真菌剂 - Google Patents

在酸性ph值下具有经增强活性的抗真菌剂 Download PDF

Info

Publication number
CN111093655A
CN111093655A CN201880059398.2A CN201880059398A CN111093655A CN 111093655 A CN111093655 A CN 111093655A CN 201880059398 A CN201880059398 A CN 201880059398A CN 111093655 A CN111093655 A CN 111093655A
Authority
CN
China
Prior art keywords
compound
infection
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880059398.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·安古洛·冈萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111093655(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis Inc filed Critical Scynexis Inc
Priority to CN202410653474.XA priority Critical patent/CN118542868A/zh
Publication of CN111093655A publication Critical patent/CN111093655A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880059398.2A 2017-08-04 2018-07-31 在酸性ph值下具有经增强活性的抗真菌剂 Pending CN111093655A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410653474.XA CN118542868A (zh) 2017-08-04 2018-07-31 在酸性ph值下具有经增强活性的抗真菌剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
US62/541,370 2017-08-04
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410653474.XA Division CN118542868A (zh) 2017-08-04 2018-07-31 在酸性ph值下具有经增强活性的抗真菌剂

Publications (1)

Publication Number Publication Date
CN111093655A true CN111093655A (zh) 2020-05-01

Family

ID=63209698

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880059398.2A Pending CN111093655A (zh) 2017-08-04 2018-07-31 在酸性ph值下具有经增强活性的抗真菌剂
CN202410653474.XA Pending CN118542868A (zh) 2017-08-04 2018-07-31 在酸性ph值下具有经增强活性的抗真菌剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410653474.XA Pending CN118542868A (zh) 2017-08-04 2018-07-31 在酸性ph值下具有经增强活性的抗真菌剂

Country Status (26)

Country Link
US (3) US11534433B2 (https=)
EP (3) EP4732902A2 (https=)
JP (1) JP7214714B2 (https=)
KR (1) KR102807716B1 (https=)
CN (2) CN111093655A (https=)
AU (2) AU2018309718B2 (https=)
BR (1) BR112020002290A2 (https=)
CA (1) CA3071940A1 (https=)
CY (1) CY1125690T1 (https=)
DK (1) DK3661503T3 (https=)
EA (1) EA202090445A1 (https=)
ES (1) ES2932658T3 (https=)
FI (1) FI3661503T3 (https=)
HR (1) HRP20221414T1 (https=)
HU (1) HUE060508T2 (https=)
LT (1) LT3661503T (https=)
MA (1) MA49751B1 (https=)
MD (1) MD3661503T2 (https=)
MX (1) MX2020001399A (https=)
PL (1) PL3661503T3 (https=)
PT (1) PT3661503T (https=)
RS (1) RS63746B1 (https=)
SI (1) SI3661503T1 (https=)
SM (1) SMT202200461T1 (https=)
TW (1) TWI805600B (https=)
WO (1) WO2019028034A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016876A2 (pt) * 2019-02-27 2021-11-03 Scynexis Inc Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201011004A (en) * 2008-08-12 2010-03-16 Merck & Co Inc Antifungal agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
HRP20220544T1 (hr) 2015-01-19 2022-08-05 Scynexis, Inc. Nove soli i polimorfi scy-078
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201011004A (en) * 2008-08-12 2010-03-16 Merck & Co Inc Antifungal agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLAIR ATKINSON ET AL.: "SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan", 《MACDOUGALL BIOMEDICAL COMMUNICATIONS》 *
周剑利等主编: "《现代妇产科诊疗与手术学》", 30 June 2017, 吉林科学技术出版社 *

Also Published As

Publication number Publication date
EP3661503B1 (en) 2022-09-07
BR112020002290A2 (pt) 2020-09-08
US20200390751A1 (en) 2020-12-17
EP4732902A2 (en) 2026-04-29
US20260000656A1 (en) 2026-01-01
JP2020529999A (ja) 2020-10-15
KR20200044823A (ko) 2020-04-29
MD3661503T2 (ro) 2023-01-31
HRP20221414T1 (hr) 2023-01-20
EA202090445A1 (ru) 2020-06-23
TW201919476A (zh) 2019-06-01
CA3071940A1 (en) 2019-02-07
FI3661503T3 (fi) 2022-12-15
HUE060508T2 (hu) 2023-03-28
AU2018309718B2 (en) 2024-07-25
MA49751B1 (fr) 2022-12-30
SMT202200461T1 (it) 2023-01-13
EP4169514B1 (en) 2026-01-28
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
SI3661503T1 (sl) 2023-01-31
RS63746B1 (sr) 2022-12-30
CN118542868A (zh) 2024-08-27
CY1125690T1 (el) 2026-02-25
LT3661503T (lt) 2022-12-12
EP4169514A1 (en) 2023-04-26
PT3661503T (pt) 2022-12-13
KR102807716B1 (ko) 2025-05-13
PL3661503T3 (pl) 2023-01-09
EP3661503A1 (en) 2020-06-10
WO2019028034A1 (en) 2019-02-07
US20230364067A1 (en) 2023-11-16
MA49751A (fr) 2020-06-10
AU2024227501A1 (en) 2024-11-07
EP4169514C0 (en) 2026-01-28
MX2020001399A (es) 2020-08-06
JP7214714B2 (ja) 2023-01-30
TWI805600B (zh) 2023-06-21
AU2018309718A1 (en) 2020-02-27
DK3661503T3 (da) 2022-12-12

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
JP7574268B2 (ja) 併用される抗真菌剤
JP7562542B2 (ja) 真菌性骨－関節感染症を治療するためのトリテルペノイド系抗真菌薬
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40109129A (zh) 在酸性ph值下具有经增强活性的抗真菌剂
TWI910099B (zh) 用於治療或預防肺囊蟲屬肺炎之三萜類抗真菌劑
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза
HK40022879B (en) Antifungal agents used in combination
HK40062347A (en) Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40022879A (en) Antifungal agents used in combination
EA047299B1 (ru) Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination